Dr Reddy's Laboratories Announces the Launch of Aripiprazole Tablets, USP Tablets in the US Market

Hyderabad : Dr. Reddy’s Laboratories Ltd announced that it has launched Aripiprazole tablets, USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, a therapeutic equivalent generic version of Abilify^® (aripiprazole) tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).

The Abilify^® brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.

Dr. Reddy’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are available in bottle count sizes of 30.

Abilify^® is a registered trademark of Otsuka Pharmaceutical Company.